Results of our phase I glioblastoma clinical trial
The findings of our phase I glioblastoma clinical trial have been published in the international Journal of Clinical Neuroscience. The results of the trial show that the treatment is safe, well-tolerated and may improve the life expectancy of patients with glioblastoma.
Glioblastoma is a severe form of brain cancer with a median overall survival of 14.6 months after diagnosis, despite intensive treatment with surgery, radiotherapy, and chemotherapy.
Results of our glioblastoma clinical trial using the GMRI treatment show that patients maintain their quality of life and performance status during treatment. They experienced very few side effects and had an overall median survival of 19.9 months. While the increase in survival is encouraging, it is not statistically significant because of the small number of participants in the trial.
We treated patients with recurrent glioblastoma
Our phase I glioblastoma clinical trial was hosted by Hutt Hospital and recruited patients with recurrent glioblastoma following conventional treatment, for whom no further treatment options were available.
How our treatment works
The trial tested the GMRI’s new cancer treatment that targets the renin-angiotensin system expressed by cancer stem cells in glioblastoma. It used commonly available low-cost, off-patent, oral medications that are safe with minimal side-effects.
Starting a phase II clinical trial for more robust results
We have approval from the Standing Committee on Therapeutic Trials and the Health and Disability Ethics Committee to undertake a phase II clinical trial. We need dedicated funding to begin the trial.
If the phase II clinical trial confirms the increase in life expectancy we observed in our phase I trial, it will be a significant milestone for cancer treatment. The most recent significant improvement for treating glioblastoma occurred over 15 years ago, with a new chemotherapy drug that improves life expectancy by two months.
Read about our phase II glioblastoma clinical trial.